Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946444 | 0.96 | HTR6 (0.75) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL5553781 | 0.91 | HTR6 (0.67) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL947267 | 0.90 | HTR6 (0.79) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL946439 | 0.90 | HTR6 (0.81) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL17515228 | 0.89 | HTR6 (1.00) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL947258 | 0.89 | HTR6 (0.72) | HTR6CYP3A4CYP2D6HTR2A | |
| SCHEMBL6265762 | 0.88 | HTR6 (0.74) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| Hydrochloric Acid SCHEMBL17515221 | 0.88 | HTR6 (0.98) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL946550 | 0.86 | HTR6 (0.76) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL17515225 | 0.85 | HTR6 (0.98) | HTR6CYP3A4CYP2D6ADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581492-B1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2008-07-16 | — | — | EP | claimed |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-10-05 | — | — | US | claimed |
| US-7875605-B2 | 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-25 | — | — | US | disclosed |
| EP-1581492-B1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2008-07-16 | — | — | EP | disclosed |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | HTR3A, HTR3C, HTR2C | HTR6 12/4885CYP3A4 58/4885CYP2D6 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.